Evidence map›Paper›PMID 37604931›Full record

ArticleBritish journal of cancer2023

Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?

Nicolas Bougas, Rodrigue S Allodji, Chiraz Fayech, Nadia Haddy, Imene Mansouri, Neige Journy, Charlotte Demoor, Julie Allard, Eric Thebault, Aurore Surun and 14 more

Abstract read
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Nicolas BougasUniversité Paris Cité, Inserm, ECEVE UMR 1123, F-75010, Paris, France. nicolas.bougas@inserm.fr.ORCID 0000-0002-2099-1724
Rodrigue S AllodjiUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.ORCID 0000-0002-1895-8415
Chiraz FayechGustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France.
Nadia HaddyUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.
Imene MansouriUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.
Neige JournyUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.
Charlotte DemoorSIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Julie AllardGustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France.
Eric ThebaultGustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France.
Aurore SurunSIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Hélène PacquementSIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Claire PluchartInstitut de Cancérologie Jean Godinot, F-51100, Reims, France.
Pierre-Yves BondiauDepartment of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France.
Delphine BercheryDepartment of Radiation Oncology, University Institute of Cancer Toulouse-Oncopôle, Toulouse, France.
Anne LaprieDepartment of Radiation Oncology, University Institute of Cancer Toulouse-Oncopôle, Toulouse, France.
Marjorie BoussacSanté publique France, the National Public Health Agency, Saint-Maurice, France.
Angela JacksonUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.
Vincent SouchardUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.
Giao Vu-BezinUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.
Christelle DufourGustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France.ORCID 0000-0001-5993-8077
Dominique Valteau-CouanetGustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France.
Florent de VathaireUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.ORCID 0000-0002-8374-9281
Brice FresneauUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France.ORCID 0000-0001-7603-7828
Agnès DumasUniversité Paris Cité, Inserm, ECEVE UMR 1123, F-75010, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to study adherence to cardiac screening in long-term childhood cancer survivors (CCS) at high risk of cardiomyopathy.

methodsThis study involved 976 5-year CCS at high risk for cardiomyopathy from the French Childhood Cancer Survivor Study. Determinants of adherence to recommended surveillance were studied using multivariable logistic regression models. Association of attendance to a long-term follow-up (LTFU) visit with completion of an echocardiogram was estimated using a Cox regression model.

resultsAmong participants, 32% had an echocardiogram within the 5 previous years. Males (adjusted RR [aRR] 0.71, 95% CI 0.58-0.86), survivors aged 36-49 (aRR 0.79, 95% CI 0.64-0.98), Neuroblastoma (aRR 0.53, 95% CI 0.30-0.91) and CNS tumour survivors (aRR 0.43, 95% CI 0.21-0.89) were less likely to adhere to recommended surveillance. Attendance to an LTFU visit was associated with completion of an echocardiogram in patients who were not previously adherent to recommendations (HR 8.20, 95% CI 5.64-11.93).

conclusionsThe majority of long-term survivors at high risk of cardiomyopathy did not adhere to the recommended surveillance. Attendance to an LTFU visit greatly enhanced the completion of echocardiograms, but further interventions need to be developed to reach more survivors.

Indexed as

Cancer SurvivorsCardiomyopathiesNeoplasmsNeuroblastomaChildHumansMaleSurvivors

Identifiers

PMID37604931
PMCPMC10575933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.